In addition, SDF-1 gene polymorphisms and CXCR4 expression in AML patients were found to correlate with higher disease risk and poorer prognosis (15), suggesting their potential as targets for therapy and markers in diagnostic evaluations. Here, CXCL12 is linked to acute myeloid leukemia.